Akero Therapeutics Inc [NASDAQ: AKRO] surged by $0.1 during the normal trading session on Monday and reaching a high of $54.825 during the day while it closed the day at $54.65.
Akero Therapeutics Inc stock has also gained 0.39% of its value over the past 7 days. However, AKRO stock has inclined by 22.48% in the 3 months of the year. Over the past six months meanwhile, it has lost -0.11% and gained 76.75% year-on date.
The market cap for AKRO stock reached $4.50 billion, with 80.15 million shares outstanding and 72.84 million shares in the current float. Compared to the average trading volume of 2.33M shares, AKRO reached a trading volume of 15307646 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Akero Therapeutics Inc [AKRO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKRO shares is $55.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKRO stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Akero Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 04, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on August 04, 2025, representing the official price target for Akero Therapeutics Inc stock. Previously, the target price had yet another raise from $35 to $63, while BofA Securities kept a Buy rating on AKRO stock. On January 27, 2025, analysts increased their price target for AKRO shares from 50 to 72.
The Price to Book ratio for the last quarter was 4.57, with the Price to Cash per share for the same quarter was set at 8.96.
AKRO stock trade performance evaluation
Akero Therapeutics Inc [AKRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.39. With this latest performance, AKRO shares gained by 1.37% in over the last four-week period, additionally sinking by -0.11% over the last 6 months – not to mention a rise of 96.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKRO stock in for the last two-week period is set at 69.17, with the RSI for the last a single of trading hit 0.22, and the three-weeks RSI is set at 0.43 for Akero Therapeutics Inc [AKRO]. The present Moving Average for the last 50 days of trading for this stock 52.92, while it was recorded at 54.60 for the last single week of trading, and 48.17 for the last 200 days.
Akero Therapeutics Inc (AKRO) Capital Structure & Debt Analysis
According to recent financial data for Akero Therapeutics Inc. ( AKRO), the Return on Equity (ROE) stands at -34.53%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -32.12%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Akero Therapeutics Inc’s Return on Invested Capital (ROIC) is -30.57%, showcasing its effectiveness in deploying capital for earnings.
Akero Therapeutics Inc (AKRO) Efficiency & Liquidity Metrics
Based on Akero Therapeutics Inc’s (AKRO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Akero Therapeutics Inc (AKRO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Akero Therapeutics Inc. (AKRO) effectively leverages its workforce, generating an average of -$4647936.51 per employee. The company’s liquidity position is robust, with a Current Ratio of 15.83% and a Quick Ratio of 15.83%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Akero Therapeutics Inc [AKRO] stock
With the latest financial reports released by the company, Akero Therapeutics Inc posted -0.99/share EPS, while the average EPS was predicted by analysts to be reported at -1.12/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.13. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Akero Therapeutics Inc go to -6.39%.
Akero Therapeutics Inc [AKRO]: Institutional Ownership
There are presently around $112.45%, or 114.12%% of AKRO stock, in the hands of institutional investors. The top three institutional holders of AKRO stocks are: JANUS HENDERSON GROUP PLC with ownership of 6.88 million shares, which is approximately 9.9425%. BLACKROCK INC., holding 5.59 million shares of the stock with an approximate value of $$131.06 million in AKRO stocks shares; and BLACKROCK INC., currently with $$127.43 million in AKRO stock with ownership which is approximately 7.8542%.
